<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04108234</url>
  </required_header>
  <id_info>
    <org_study_id>HR071603-101</org_study_id>
    <nct_id>NCT04108234</nct_id>
  </id_info>
  <brief_title>A Study of HR071603(Ketamine Nasal Spray) in Healthy Subjects</brief_title>
  <official_title>Safety, Tolerance and Pharmacokinetics of Hydrochloric Acid (R) -Ketamine Nasal Spray in Healthy Subjects: A Randomized, Double Blind, Placebo-Controlled Phase I Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the safety and pharmacokinetics of HR071603 in&#xD;
      healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2019</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>HR071603 monotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (Safety and Tolerability)</measure>
    <time_frame>Pre-dose to Day8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter-Area under drug-time curve (AUC)</measure>
    <time_frame>Pre-dose to Day2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter-peak time (Tmax)</measure>
    <time_frame>Pre-dose to Day2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter-peak concentration (Cmax)</measure>
    <time_frame>Pre-dose to Day2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter-half-life (t1/2)</measure>
    <time_frame>Pre-dose to Day2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter-apparent clearance rate (CL/F)</measure>
    <time_frame>Pre-dose to Day2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter-apparent distribution volume (Vz/F)</measure>
    <time_frame>Pre-dose to Day2</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Treatment group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HR071603,nasal spray,dose escalation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, nasal spray</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HR071603</intervention_name>
    <description>HR071603 monotherapy ,nasal spray</description>
    <arm_group_label>Treatment group A</arm_group_label>
    <other_name>R-ketamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo,nasal spray</description>
    <arm_group_label>Treatment group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Obtain informed consent prior to the start of any activity related to the trial, and&#xD;
             have a thorough understanding of the purpose and meaning of the trial and be willing&#xD;
             to comply with the protocol;&#xD;
&#xD;
          2. Healthy males aged between 18 and 45 (including both ends);&#xD;
&#xD;
          3. Weight ≥ 50kg, body mass index (BMI) in the range of 18.5 ~ 23.9 (including both&#xD;
             ends);&#xD;
&#xD;
          4. During the trial and within 30 days after the administration, willing to take&#xD;
             contraceptive measures and ensure that no sperm is donated.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A subject considered by the investigator to be unsuitable for nasal spray&#xD;
             administration;&#xD;
&#xD;
          2. Allergic to any component of the study drug;&#xD;
&#xD;
          3. The underlying disease is not suitable for participation in the trial;&#xD;
&#xD;
          4. 12-lead ECG results in the screening period are abnormal and clinically significant&#xD;
&#xD;
          5. Liver dysfunction;&#xD;
&#xD;
          6. Serum creatinine &gt; 1.2 × ULN during screening period;&#xD;
&#xD;
          7. Screening for infectious diseases screening hepatitis B surface antigen (HBsAg),&#xD;
             hepatitis C antibody (HCVAb), syphilis antibody, human immunodeficiency virus (HIV)&#xD;
             antibody test positive;&#xD;
&#xD;
          8. Subject has been thoroughly examined, and the results are abnormal and clinically&#xD;
             significant;&#xD;
&#xD;
          9. Major operations were performed within 3 months before the screening period.&#xD;
&#xD;
         10. Donate whole blood/plasma within one month before the screening period, or donate&#xD;
             whole blood/plasma more than 400 ml within three months before the screening period;&#xD;
&#xD;
         11. Positive urine drug test;&#xD;
&#xD;
         12. The alcohol breath test is positive; or the average daily intake of alcohol exceeds&#xD;
             15g;&#xD;
&#xD;
         13. Nicotine test is positive;&#xD;
&#xD;
         14. History of drug abuse or alcohol abuse;&#xD;
&#xD;
         15. In the past three months, over five cups of coffee or tea per day were consumed in an&#xD;
             average;&#xD;
&#xD;
         16. Any prescription drugs, over-the-counter drugs and health products were used within 2&#xD;
             weeks before screening.&#xD;
&#xD;
         17. Participated in clinical trials of any drug or medical device within 3 months before&#xD;
             screening ;&#xD;
&#xD;
         18. Any other medical or psychological condition, which in the opinion of the&#xD;
             Investigator, might create undue risk to the participant or interfere with the&#xD;
             participant's ability to comply with the protocol requirements, or to complete the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianjun Zou</last_name>
    <phone>021-68868570</phone>
    <email>zoujianjun@hrglobe.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>xiaoli cai</last_name>
    <phone>02161623506</phone>
    <email>caixiaoli@hrglobe.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing AnDing hospital affiliated to Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chuanyue Wang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 26, 2019</study_first_submitted>
  <study_first_submitted_qc>September 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2019</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

